JP2002540168A5 - - Google Patents

Download PDF

Info

Publication number
JP2002540168A5
JP2002540168A5 JP2000607657A JP2000607657A JP2002540168A5 JP 2002540168 A5 JP2002540168 A5 JP 2002540168A5 JP 2000607657 A JP2000607657 A JP 2000607657A JP 2000607657 A JP2000607657 A JP 2000607657A JP 2002540168 A5 JP2002540168 A5 JP 2002540168A5
Authority
JP
Japan
Prior art keywords
dengue
virus
den
pdk
passaged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000607657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002540168A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/008199 external-priority patent/WO2000057907A2/en
Publication of JP2002540168A publication Critical patent/JP2002540168A/ja
Publication of JP2002540168A5 publication Critical patent/JP2002540168A5/ja
Pending legal-status Critical Current

Links

JP2000607657A 1999-03-26 2000-03-24 多価デングウイルスワクチン Pending JP2002540168A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12631399P 1999-03-26 1999-03-26
US18172400P 2000-02-11 2000-02-11
US60/181,724 2000-02-11
US60/126,313 2000-02-11
PCT/US2000/008199 WO2000057907A2 (en) 1999-03-26 2000-03-24 Multivalent dengue virus vaccine

Publications (2)

Publication Number Publication Date
JP2002540168A JP2002540168A (ja) 2002-11-26
JP2002540168A5 true JP2002540168A5 (https=) 2007-05-31

Family

ID=26824502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000607657A Pending JP2002540168A (ja) 1999-03-26 2000-03-24 多価デングウイルスワクチン

Country Status (12)

Country Link
US (2) US6638514B1 (https=)
EP (1) EP1165127B1 (https=)
JP (1) JP2002540168A (https=)
KR (1) KR100721745B1 (https=)
CN (1) CN1191092C (https=)
AT (1) ATE419006T1 (https=)
AU (1) AU779280B2 (https=)
CA (1) CA2368674A1 (https=)
DE (1) DE60041250D1 (https=)
ES (1) ES2322327T3 (https=)
MX (1) MXPA01009683A (https=)
WO (1) WO2000057907A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
DK2290109T3 (da) 2001-05-22 2014-11-10 Us Gov Health & Human Serv Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CL2008003202A1 (es) * 2007-10-29 2009-11-27 Boehringer Ingelheim Vetmedica Inc Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
EP2376923A4 (en) * 2008-12-22 2012-08-15 Children S Res Inst METHOD FOR DETECTING SEPSIS
AR075437A1 (es) 2009-02-17 2011-03-30 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento
NZ597000A (en) * 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
ES2436317T3 (es) 2010-05-07 2013-12-30 Deutsches Krebsforschungszentrum Parvovirus de roedor modificado capaz de propagarse y difundirse en gliomas humanos
BR112015031226A2 (pt) * 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina
EP3236997B1 (en) 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Dengue virus vaccine compositions and methods of use thereof
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN108291205A (zh) 2015-09-26 2018-07-17 普莱瓦克斯免疫肿瘤学公司 用于产生树突细胞的组合物和方法
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
WO2018165373A1 (en) * 2017-03-08 2018-09-13 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
KR20200023375A (ko) * 2017-06-15 2020-03-04 프라임벡스 이뮤노-온콜로지, 인크. 뎅기 바이러스 및 수지상 세포를 이용하는 암 요법을 위한 조성물 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06181792A (ja) * 1992-06-05 1994-07-05 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法、およびそれに用いる組み換えウイルス
EP0705109B2 (en) 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0948256A4 (en) * 1996-10-28 2007-10-24 Univ Washington INDUCTION OF VIRAL MUTATIONS BY INTRODUCTION TO ERROR-CODED RIBONUCLEOSIDE ANALOGUES IN VIRAL RNA
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン

Similar Documents

Publication Publication Date Title
JP2002540168A5 (https=)
AU2012269907B2 (en) Vaccine composition comprising an inactivated chikungunya virus strain
JP2019511533A5 (https=)
JP2010505801A5 (https=)
JP2026031938A5 (https=)
JP5091385B2 (ja) 弱毒生ワクチン
CA2116980A1 (en) Chimeric and/or growth-restricted flaviviruses
EP2345665A3 (en) Flavivirus NS1 subunit vaccine
WO2000057907A3 (en) Multivalent dengue virus vaccine
EP3010536A1 (en) Dengue virus vaccine compositions and methods of use thereof
US7790173B2 (en) Pharmaceutical compound capable of induce immune protective response against Dengue virus having the capsid protein of the Dengue virus
CA2341354C (en) Dengue viruses that are replication defective in mosquitos for use as vaccines
Chia et al. Fragment of Japanese encephalitis virus envelope protein produced in Escherichia coli protects mice from virus challenge
ES2517615T3 (es) Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
EP3355916A1 (en) Stable live attenuated recombinant dengue vaccine
EP4604994A1 (en) Dengue vaccine formulation
Chiba et al. A case of poliomyelitis associated with infection of wild poliovirus in Qinghai Province, China, in October 1999
Simasathein et al. Dengue vaccine
WO2002074963A1 (en) Dengue viruses that are replication defective in mosquitos for use as vaccines
Putnak et al. Inactivated dengue virus vaccine
Rombaut History and future of polivaccination, a personal account
Kelly et al. Recombinant vaccine against dengue virus
HK1120431A (en) Recombinant flavivirus vaccines
MY145463A (en) Flavivirus ns1 subunit vaccine